IN THE SPOTLIGHT

New NSCLC Trial Data Reignite Adjuvant vs Neoadjuvant Debate

New NSCLC Trial Data Reignite Adjuvant vs Neoadjuvant Debate

New IO Paper Alert: Dual Immune Checkpoint Blockade in NSCLC Shows Long-Term Survival Gains

New IO Paper Alert: Dual Immune Checkpoint Blockade in NSCLC Shows Long-Term Survival Gains

Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC

Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC

Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC

Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC

BioInvent Launches Phase 2a Trial for BI-1206 in NSCLC and Uveal Melanoma

BioInvent Launches Phase 2a Trial for BI-1206 in NSCLC and Uveal Melanoma

BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma

BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma

NICE Recommends Lorlatinib for ALK-Positive NSCLC

NICE Recommends Lorlatinib for ALK-Positive NSCLC

Ivonescimab/Chemo Improves PFS in Post-TKI EGFR-Mutant NSCLC

Ivonescimab/Chemo Improves PFS in Post-TKI EGFR-Mutant NSCLC

SABR Ties With SOC Surgery in NSCLC Survival

SABR Ties With SOC Surgery in NSCLC Survival

Zongertinib’s Efficacy, Safety in HER2-Mutant NSCLC

Zongertinib’s Efficacy, Safety in HER2-Mutant NSCLC